Atabecestat
Asymptomatic Amyloid-positive
Janssen Research & Development, LLCSmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Asymptomatic Amyloid-positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acoramidis Bayer | Phase 4 | BBB |
DEXAMETHASONE Ascentage Pharma Group Inc. | Phase 3 | BB |
Empagliflozin Columbia University | Phase 4 | BB |
fx-1006a Pfizer | Phase 4 | BB |
Cyclophosphamide University of Alabama at Birmingham | Phase 2 | BB |
View all 38 →
Same molecule, other indications
Atabecestat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →